Synthesis and transport of outer membrane components across the Gram-negative cell envelope
外膜成分的合成和跨革兰氏阴性细胞包膜的运输
基本信息
- 批准号:10680968
- 负责人:
- 金额:$ 57.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-27 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:Antibiotic ResistanceAntibioticsAntimicrobial ResistanceAttentionBacteriaBacterial InfectionsBiochemicalBiogenesisBiological ModelsBiologyCellsCessation of lifeClinicalComplexCytoplasmDataDedicationsDevelopmentEncapsulatedEnergy-Generating ResourcesEscherichia coliFamilyFutureGeneticGlycerophospholipidsGram-Negative BacteriaHealthcareHomeostasisHydrophobicityInfectionLipidsLipopolysaccharidesLipoproteinsMaintenanceMembraneMembrane LipidsMembrane ProteinsMethodologyMolecularMolecular ChaperonesMonitorMovementMulti-Drug ResistanceOrganismPathway interactionsPeptidoglycanProteinsReportingResistanceRoleSideSurfaceSystemSystems Analysisantimicrobialaqueousbeta barrelcell envelopedesigneconomic costfightingglobal healthlipid transportlipophilicitymembermembrane assemblymembrane biogenesisnew therapeutic targetnovelnovel therapeuticspathogenperiplasmpreventprotein complex
项目摘要
Abstract
The increasing rise in antibiotic resistance and the diminished discovery of new antimicrobials threatens global
healthcare. Of particular concern are Gram-negative pathogens, organisms with an additional outer membrane
(OM) that provides intrinsic resistance to multiple classes of antibiotics. Unlike the inner membrane (IM) that is
composed solely of glycerophospholipids (GPLs), the OM is asymmetrical with GPLs found in the inner leaflet
and lipopolysaccharide (LPS) localized to the outer leaflet. This unique membrane asymmetry affords
protection from large polar molecules, as well as lipophilic compounds, creating an impervious barrier. Since
the OM is essential, pathways required for its assembly are key targets for antimicrobial design. Currently,
there are no antibiotics that directly target OM biogenesis in clinical use. Thus, it remains critical to investigate
cell envelope biogenesis for future and current antimicrobial design.
Over the last few decades, we have expanded our understanding of OM assembly revealing new targets for
antimicrobial design. However, one major gap remained. How are GPLs transported from the IM to the OM
across the aqueous periplasm? Recently, we discovered that key members of the AsmA-like family (YhdP,
TamB, and YdbH) are critical for OM integrity and involved in GPL transport. We found that YhdP, TamB, and
YdbH are redundant in their role in OM lipid homeostasis; however, they are not equivalent. Notably, all three
proteins share homology and structural features with eukaryotic GPL transporters and are capable of spanning
the periplasm. The overall objective of this application is to investigate the molecular mechanisms required
for the assembly and maintenance of the Gram-negative OM. More specifically, we will characterize pathways
required to transport GPLs across the cell envelope using E. coli as the model system. In the current
application we will (i) characterize the major GPL transporters (YhdP, TamB, and YdbH), (ii) identify accessory
proteins required for GPL transbilayer movement, and (iii) determine how loss of these systems impact OM
lipid homeostasis and antibiotic resistance.
抽象的
抗生素耐药性的增加以及新抗菌剂的发现减少威胁着全球
卫生保健。特别关注的是革兰氏阴性病原体,具有附加外膜的生物
(OM)对多种类别的抗生素具有内在的抗性。与内膜(IM)不同
OM仅由甘油磷脂(GPLS)组成,与内部小叶中发现的GPL是不对称的
和脂多糖(LPS)位于外部小叶中。这种独特的膜不对称提供
防止大型极性分子以及亲脂化合物,从而产生不透水的屏障。自从
OM是必不可少的,其组装所需的途径是抗菌设计的关键目标。现在,
在临床用途中,没有直接靶向OM生物发生的抗生素。因此,调查仍然至关重要
用于未来和当前抗菌设计的细胞包膜生物发生。
在过去的几十年中,我们扩展了对OM集会的理解,揭示了新的目标
抗菌设计。但是,仍然存在一个主要差距。 GPLS如何从IM运输到OM
穿过骨质水性?最近,我们发现了类似Asma的家庭的主要成员(YHDP,
TAMB和YDBH)对于OM完整性至关重要,并且参与GPL运输。我们发现YHDP,Tamb和
YDBH在OM脂质稳态中的作用是多余的。但是,它们不是等效的。值得注意的是,这三个
蛋白质与真核GPL转运蛋白共享同源性和结构特征,并且能够跨越
周期。该应用的总体目的是研究所需的分子机制
用于革兰氏阴性OM的组装和维护。更具体地说,我们将表征途径
需要使用大肠杆菌作为模型系统将GPLS运输在细胞包膜上。在电流中
应用程序我们将(i)表征主要的GPL转运蛋白(YHDP,TAMB和YDBH),(ii)标识附件
GPL Transbilayer运动所需的蛋白质,以及(iii)确定这些系统丢失如何影响OM
脂质稳态和抗生素耐药性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Stephen Trent其他文献
Michael Stephen Trent的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Stephen Trent', 18)}}的其他基金
The role of cardiolipin in the biogenesis of the Gram-negative bacterial cell envelope
心磷脂在革兰氏阴性细菌细胞包膜生物发生中的作用
- 批准号:
10731444 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10113527 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10542396 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii
多重耐药病原体鲍曼不动杆菌的细胞包膜
- 批准号:
10328269 - 财政年份:2020
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
10159193 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
10403653 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Molecular mechanisms required for the maintenance of the gram-negative outer membrane
维持革兰氏阴性外膜所需的分子机制
- 批准号:
9917747 - 财政年份:2018
- 资助金额:
$ 57.98万 - 项目类别:
Development of a novel vaccine platform: Surface Antigen/Adjuvant Vaccine Engineering (SAAVE)
新型疫苗平台的开发:表面抗原/佐剂疫苗工程(SAAVE)
- 批准号:
9899172 - 财政年份:2017
- 资助金额:
$ 57.98万 - 项目类别:
Rethinking the barrier: How a Gram-negative bacterium alters its surface to become multidrug resistant
重新思考屏障:革兰氏阴性细菌如何改变其表面以产生多重耐药性
- 批准号:
9102680 - 财政年份:2015
- 资助金额:
$ 57.98万 - 项目类别:
相似国自然基金
结合态抗生素在水产品加工过程中的消解机制与产物毒性解析
- 批准号:32302247
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于Fe-N-BC/PMS体系的自由基与非自由基协同降解地下水中磺胺类抗生素的机制研究
- 批准号:42377036
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于高通量测序和培养组学的伴侣动物-人抗生素抗性基因分布特征及传播研究
- 批准号:82373646
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
微藻-细菌协同降解抗生素及其共适应机制
- 批准号:42377367
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
多环芳烃影响大肠杆菌抗生素耐药性进化的分子机制
- 批准号:32301424
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
噻唑啉-吡啶酮化合物作为结核病新药
- 批准号:
10698829 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
A Randomized Pilot and Feasibility Study of a cultuRE-Directed approach to Urinary traCT Infection symptoms in older womeN: a mixed methods evaluation - the REDUCTION trial
针对老年女性尿路感染症状的文化导向方法的随机试验和可行性研究:混合方法评估 - REDUCTION 试验
- 批准号:
10586250 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Infection-Dependent Vulnerabilities of Gram-negative Bacterial Pathogens
革兰氏阴性细菌病原体的感染依赖性脆弱性
- 批准号:
10592676 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection
一种新型、非抗生素、微生物组导向剂,用于预防术后感染
- 批准号:
10600765 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别:
Development of Targeted Antipseudomonal Bactericidal Prodrugs
靶向抗假单胞菌杀菌前药的开发
- 批准号:
10678074 - 财政年份:2023
- 资助金额:
$ 57.98万 - 项目类别: